BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mazzaferro V. Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. Hepatology. 2016;63:1707-1717. [PMID: 26703761 DOI: 10.1002/hep.28420] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 13.2] [Reference Citation Analysis]
Number Citing Articles
1 Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, Cescon M, Di Sandro S, Yi-Feng H, Lauterio A, Bongini M, Cucchetti A. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology. 2018;154:128-139. [PMID: 28989060 DOI: 10.1053/j.gastro.2017.09.025] [Cited by in Crossref: 178] [Cited by in F6Publishing: 163] [Article Influence: 44.5] [Reference Citation Analysis]
2 Minici R, Ammendola M, Manti F, Siciliano MA, Giglio E, Minici M, Melina M, Currò G, Laganà D. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization as a Bridging Therapy in Patients with Early Stage Hepatocellular Carcinoma and Child-Pugh Stage B Eligible for Liver Transplant. Front Pharmacol 2021;12:634084. [PMID: 33897421 DOI: 10.3389/fphar.2021.634084] [Reference Citation Analysis]
3 Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World J Gastroenterol 2018; 24(32): 3626-3636 [PMID: 30166858 DOI: 10.3748/wjg.v24.i32.3626] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
4 Di Sandro S, Sposito C, Lauterio A, Najjar M, Droz Dit Busset M, Buscemi V, Flores Reyes M, De Carlis R, Mazzaferro V, De Carlis L. Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients. J Am Coll Surg 2018;226:1147-59. [PMID: 29574178 DOI: 10.1016/j.jamcollsurg.2018.03.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
5 De Carlis L, Di Sandro S, Centonze L, Lauterio A, Buscemi V, De Carlis R, Ferla F, Sguinzi R, Okolicsanyi S, Belli L, Strazzabosco M. Liver-allocation policies for patients affected by HCC in Europe. Curr Transplant Rep 2016;3:313-8. [PMID: 28473952 DOI: 10.1007/s40472-016-0117-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
6 Xiao Y, Chen B, Yang K, Wang Q, Liu P, Gu Y, Zhong Q, Liu Z, He Y, Liu Q. Down-regulation of MARCO associates with tumor progression in hepatocellular carcinoma. Exp Cell Res 2019;383:111542. [PMID: 31381879 DOI: 10.1016/j.yexcr.2019.111542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Yao FY, Fidelman N, Mehta N. The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma. Semin Liver Dis 2021;41:117-27. [PMID: 33788207 DOI: 10.1055/s-0040-1716565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Moeckli B, Majno P, Orci LA, Peloso A, Toso C. Liver Transplantation Selection and Allocation Criteria for Hepatocellular Carcinoma: A European Perspective. Semin Liver Dis 2021;41:172-81. [PMID: 33957694 DOI: 10.1055/s-0041-1723032] [Reference Citation Analysis]
9 Di Sandro S, Bagnardi V, Cucchetti A, Lauterio A, De Carlis R, Benuzzi L, Danieli M, Botta F, Centonze L, Najjar M, De Carlis L. From a Philosophical Framework to a Valid Prognostic Staging System of the New "Comprehensive Assessment" for Transplantable Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E741. [PMID: 31142035 DOI: 10.3390/cancers11060741] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
10 Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, Colledan M, Salizzoni M, Romagnoli R, Antonelli B, Vivarelli M, Tisone G, Rossi M, Gruttadauria S, Di Sandro S, De Carlis R, Lucà MG, De Giorgio M, Mirabella S, Belli L, Fagiuoli S, Martini S, Iavarone M, Svegliati Baroni G, Angelico M, Ginanni Corradini S, Volpes R, Mariani L, Regalia E, Flores M, Droz Dit Busset M, Sposito C. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020;21:947-56. [PMID: 32615109 DOI: 10.1016/S1470-2045(20)30224-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 27.0] [Reference Citation Analysis]
11 Lai Q, Vitale A, Halazun K, Iesari S, Viveiros A, Bhangui P, Mennini G, Wong T, Uemoto S, Lin CC, Mittler J, Ikegami T, Zhe Y, Zheng SS, Soejima Y, Hoppe-Lotichius M, Chen CL, Kaido T, Lo CM, Rossi M, Soin AS, Finkenstedt A, Emond JC, Cillo U, Lerut J. Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. Cancers (Basel) 2020;12:E452. [PMID: 32075133 DOI: 10.3390/cancers12020452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
12 Toniutto P, Bitetto D, Fornasiere E, Fumolo E. Challenges and future developments in liver transplantation. Minerva Gastroenterol Dietol 2019;65:136-52. [PMID: 30303340 DOI: 10.23736/S1121-421X.18.02529-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
13 Aravinthan AD, Bruni SG, Doyle AC, Thein HH, Goldaracena N, Issachar A, Lilly LB, Selzner N, Bhat M, Sreeharsha B, Selzner M, Ghanekar A, Cattral MS, McGilvray ID, Greig PD, Renner EL, Grant DR, Sapisochin G. Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma. Ann Surg Oncol 2017;24:1843-51. [PMID: 28160137 DOI: 10.1245/s10434-017-5789-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
14 Mazzaferro V, Droz dit Busset M, Bhoori S. Alpha-fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better: Hepatology Elsewhere. Hepatology 2018;68:775-7. [DOI: 10.1002/hep.29835] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. Am J Transplant 2019;19:2210-8. [PMID: 30861298 DOI: 10.1111/ajt.15353] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
16 McVey JC, Sasaki K, Firl DJ. Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepat Oncol 2020;7:HEP26. [PMID: 32774836 DOI: 10.2217/hep-2020-0003] [Reference Citation Analysis]
17 De Carlis R, Di Sandro S, Lauterio A, Ferla F, Dell'Acqua A, Zanierato M, De Carlis L. Successful donation after cardiac death liver transplants with prolonged warm ischemia time using normothermic regional perfusion. Liver Transpl. 2017;23:166-173. [PMID: 27783454 DOI: 10.1002/lt.24666] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
18 Kuroda H, Nagasawa T, Fujiwara Y, Sato H, Abe T, Kooka Y, Endo K, Oikawa T, Sawara K, Takikawa Y. Comparing the Safety and Efficacy of Microwave Ablation Using ThermosphereTM Technology versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:1295. [PMID: 33803926 DOI: 10.3390/cancers13061295] [Reference Citation Analysis]
19 Bhat M, Ghali P, Dupont B, Hilzenrat R, Tazari M, Roy A, Chaudhury P, Alvarez F, Carrier M, Bilodeau M. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics. J Hepatol 2017;66:374-81. [PMID: 27751840 DOI: 10.1016/j.jhep.2016.10.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
20 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology 2017;67:173-83. [DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 76] [Article Influence: 17.3] [Reference Citation Analysis]
21 Pommergaard HC, Rostved AA, Adam R, Thygesen LC, Salizzoni M, Gómez Bravo MA, Cherqui D, Filipponi F, Boudjema K, Mazzaferro V, Soubrane O, García-Valdecasas JC, Prous JF, Pinna AD, O'Grady J, Karam V, Duvoux C, Rasmussen A; European Liver and Intestine Transplant Association (ELITA). Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. HPB (Oxford) 2018;20:768-75. [PMID: 29622402 DOI: 10.1016/j.hpb.2018.03.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
22 Kapoor H, Nisiewicz MJ, Jayavarapu R, Gedaly R, Raissi D. Early Outcomes with Single-antenna High-powered Percutaneous Microwave Ablation for Primary and Secondary Hepatic Malignancies: Safety, Effectiveness, and Predictors of Ablative Failure. J Clin Imaging Sci 2020;10:10. [PMID: 32257586 DOI: 10.25259/JCIS_173_2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Burra P, Zanetto A, Germani G. Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E46. [PMID: 29425151 DOI: 10.3390/cancers10020046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
24 Sapisochin G, Hibi T, Toso C, Man K, Berenguer M, Heimbach J, Greten TF, Pugh TJ, Dawson LA, Mazzaferro V. Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities. Ann Surg 2021;273:483-93. [PMID: 33065633 DOI: 10.1097/SLA.0000000000004071] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
25 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1926] [Article Influence: 707.3] [Reference Citation Analysis]
26 De Carlis R, Di Sandro S, Lauterio A, Botta F, Ferla F, Andorno E, Bagnardi V, De Carlis L. Liver Grafts From Donors After Circulatory Death on Regional Perfusion With Extended Warm Ischemia Compared With Donors After Brain Death: XXXX. Liver Transpl 2018;24:1523-35. [DOI: 10.1002/lt.25312] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 12.3] [Reference Citation Analysis]
27 Renner P, Da Silva T, Schnitzbauer AA, Verloh N, Schlitt HJ, Geissler EK. Hepatocellular carcinoma progression during bridging before liver transplantation. BJS Open 2021;5:zrab005. [PMID: 33839747 DOI: 10.1093/bjsopen/zrab005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lai Q, Vitale A, Iesari S, Finkenstedt A, Mennini G, Spoletini G, Hoppe-Lotichius M, Vennarecci G, Manzia TM, Nicolini D. Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology. 2017;66:1910-1919. [PMID: 28653750 DOI: 10.1002/hep.29342] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 12.8] [Reference Citation Analysis]
29 Mazzaferro V, Battiston C, Sposito C. Pro (With Caution): Extended oncologic indications in liver transplantation: Mazzaferro et al. Liver Transpl 2018;24:98-103. [DOI: 10.1002/lt.24963] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
30 Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl. 2018;24:294-303. [PMID: 29024405 DOI: 10.1002/lt.24955] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
31 Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol 2018;16:955-64. [PMID: 29175528 DOI: 10.1016/j.cgh.2017.11.037] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 10.3] [Reference Citation Analysis]
32 Amorim J, França M, Perez-girbes A, Torregrosa A, Martí-bonmatí L. Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol 2020;45:3119-28. [DOI: 10.1007/s00261-020-02470-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
33 Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1136-42. [DOI: 10.1097/tp.0000000000003174] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 16.0] [Reference Citation Analysis]
34 Gundlach JP, Schmidt S, Bernsmeier A, Günther R, Kataev V, Trentmann J, Schäfer JP, Röcken C, Becker T, Braun F. Indication of Liver Transplantation for Hepatocellular Carcinoma Should Be Reconsidered in Case of Microvascular Invasion and Multilocular Tumor Occurrence. J Clin Med 2021;10:1155. [PMID: 33801887 DOI: 10.3390/jcm10061155] [Reference Citation Analysis]
35 Unzueta A, Cabrera R. Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma. Clinics in Liver Disease 2017;21:231-51. [DOI: 10.1016/j.cld.2016.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
36 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 984] [Article Influence: 526.7] [Reference Citation Analysis]
37 Rubin A, Berenguer M. Remnant vital tissue following locoregional therapy for hepatocellular carcinoma: Another player in the game. Transpl Int. 2018;. [PMID: 29710433 DOI: 10.1111/tri.13274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Ferrer-Fàbrega J, Sampson-Dávila J, Forner A, Sapena V, Díaz A, Vilana R, Navasa M, Fondevila C, Miquel R, Ayuso C, García-Valdecasas JC, Bruix J, Reig M, Fuster J. Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. J Hepatol 2021:S0168-8278(21)00435-9. [PMID: 34171433 DOI: 10.1016/j.jhep.2021.06.015] [Reference Citation Analysis]
39 Brusset B, Dumortier J, Cherqui D, Pageaux GP, Boleslawski E, Chapron L, Quesada JL, Radenne S, Samuel D, Navarro F, Dharancy S, Decaens T. Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model. Cancers (Basel) 2021;13:2480. [PMID: 34069594 DOI: 10.3390/cancers13102480] [Reference Citation Analysis]
40 Pommergaard HC, Rostved AA, Adam R, Rasmussen A, Salizzoni M, Bravo MAG, Cherqui D, De Simone P, Houssel-Debry P, Mazzaferro V, Soubrane O, García-Valdecasas JC, Prous JF, Pinna AD, O'Grady J, Karam V, Duvoux C, Thygesen LC. Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry. Liver Cancer 2020;9:455-67. [PMID: 32999871 DOI: 10.1159/000507397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Levi Sandri GB, Lai Q. Twenty years after: from Milan criteria to a "blended" approach. Transl Gastroenterol Hepatol 2017;2:62. [PMID: 28815222 DOI: 10.21037/tgh.2017.07.01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Mehta N, Dodge JL, Grab JD, Yao FY. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology 2020;71:943-54. [PMID: 31344273 DOI: 10.1002/hep.30879] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 20.5] [Reference Citation Analysis]
43 Halazun KJ, Sapisochin G, von Ahrens D, Agopian VG, Tabrizian P. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. Int J Surg. 2020;82S:61-69. [PMID: 32707331 DOI: 10.1016/j.ijsu.2020.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Bredt LC, Peres LAB. Artificial neural network for prediction of acute kidney injury after liver transplantation for cirrhosis and hepatocellular carcinoma. Artif Intell Cancer 2021; 2(5): 51-59 [DOI: 10.35713/aic.v2.i5.51] [Reference Citation Analysis]
45 Sangiovanni A, Colombo M. Bridging to liver transplantation patients with a hepatocellular carcinoma within Milan criteria: how worth is it? Hepatobiliary Surg Nutr 2018;7:202-5. [PMID: 30046574 DOI: 10.21037/hbsn.2018.03.12] [Reference Citation Analysis]
46 Pommergaard HC, Rostved AA, Adam R, Thygesen LC, Salizzoni M, Gómez Bravo MA, Cherqui D, De Simone P, Boudjema K, Mazzaferro V, Soubrane O, García-Valdecasas JC, Fabregat Prous J, Pinna AD, O'Grady J, Karam V, Duvoux C, Rasmussen A; European Liver and Intestine Transplant Association (ELITA). Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. Transpl Int 2018;31:531-9. [PMID: 29380442 DOI: 10.1111/tri.13123] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
47 Manzini G, Henne-Bruns D, Porzsolt F, Kremer M. Is there a standard for surgical therapy of hepatocellular carcinoma in healthy and cirrhotic liver? BMJ Open Gastroenterol. 2017;4:e000129. [PMID: 28405349 DOI: 10.1136/bmjgast-2016-000129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
48 Soin AS, Bhangui P, Kataria T, Baijal SS, Piplani T, Gautam D, Choudhary NS, Thiagarajan S, Rastogi A, Saraf N, Saigal S. Experience With LDLT in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis Postdownstaging. Transplantation 2020;104:2334-45. [PMID: 32032291 DOI: 10.1097/TP.0000000000003162] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 11.0] [Reference Citation Analysis]
49 Mulligan DC. The ongoing quest to find the appropriate patients to transplant with hepatocellular carcinoma: Milan to san Francisco to Toronto and beyond: Mulligan. Hepatology 2016;64:1853-5. [DOI: 10.1002/hep.28841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
50 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 145] [Article Influence: 36.5] [Reference Citation Analysis]
51 Ju MR, Yopp AC. Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience. Ann Gastroenterol Surg 2020;4:208-15. [PMID: 32490334 DOI: 10.1002/ags3.12316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
52 Colombo M, Torzilli G. Expanding transplantation of patients with a liver cancer without harming allocation: a priority in the era of scarce donation. Hepatobiliary Surg Nutr 2017;6:339-41. [PMID: 29152483 DOI: 10.21037/hbsn.2017.05.13] [Reference Citation Analysis]
53 Manzia TM, Lai Q, Iesari S, Perera MTPR, Komuta M, Carvalheiro A, Shah T, Angelico R, Quaranta C, Nicolini D, Montalti R, Scarpelli M, Palmieri G, Orlacchio A, Vivarelli M, Angelico M, Lerut J, Tisone G. Impact of remnant vital tissue after locoregional treatment and liver transplant in hepatocellular cancer patients, a multicentre cohort study. Transpl Int. 2018;. [PMID: 29572974 DOI: 10.1111/tri.13153] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
54 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
55 Biolato M, Marrone G, Miele L, Gasbarrini A, Grieco A. Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. World J Gastroenterol 2017; 23(18): 3195-3204 [PMID: 28566879 DOI: 10.3748/wjg.v23.i18.3195] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Cucchetti A, Serenari M, Sposito C, Di Sandro S, Mosconi C, Vicentin I, Garanzini E, Mazzaferro V, De Carlis L, Golfieri R, Spreafico C, Vanzulli A, Buscemi V, Ravaioli M, Ercolani G, Pinna AD, Cescon M. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. Journal of Hepatology 2020;73:342-8. [DOI: 10.1016/j.jhep.2020.03.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
57 Toniutto P, Zanetto A, Ferrarese A, Burra P. Current challenges and future directions for liver transplantation. Liver Int. 2017;37:317-327. [PMID: 27634369 DOI: 10.1111/liv.13255] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
58 Schoenberg MB, Ehmer U, Umgelter A, Bucher JN, Koch DT, Börner N, Nieß H, Denk G, De Toni EN, Seidensticker M, Andrassy J, Angele MK, Werner J, Guba MO. Liver transplantation versus watchful waiting in hepatocellular carcinoma patients with complete response to bridging therapy - a retrospective observational study. Transpl Int 2021;34:465-73. [PMID: 33368655 DOI: 10.1111/tri.13808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Mazzaferro V, Danelli P, Torzilli G, Droz Dit Busset M, Virdis M, Sposito C. A Combined Approach to Priorities of Surgical Oncology During the COVID-19 Epidemic. Ann Surg 2020;272:e84-6. [PMID: 32675506 DOI: 10.1097/SLA.0000000000004005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
60 Mehta N, Dodge JL, Roberts JP, Yao FY. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival. J Hepatol 2021;74:829-37. [PMID: 33188904 DOI: 10.1016/j.jhep.2020.10.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
61 Cillo U, Vitale A, Polacco M, Fasolo E. Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit. Hepatology. 2017;65:1741-1748. [PMID: 28010048 DOI: 10.1002/hep.28998] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
62 Sposito C, Cucchetti A, Mazzaferro V. Reply. Gastroenterology 2018;154:2276-7. [DOI: 10.1053/j.gastro.2018.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]